Moderna Ships First Made-in-Canada mRNA Vaccines, Enhancing National Health Security

Moderna, Inc. continues to innovate in mRNA therapeutics and vaccines, expanding beyond COVID-19 to address diseases such as influenza, RSV, cancer, and rare genetic conditions, while integrating AI and machine learning to enhance R&D processes. Despite recent stock declines due to unsubstantiated reports linking its COVID-19 vaccine to child deaths and regulatory changes like Florida's lifting of vaccine mandates, Moderna emphasizes transparency and the safety of its vaccines, supported by over a billion doses administered globally. A significant milestone was achieved in September 2025 with the first fully Canadian-manufactured mRNA vaccines being shipped across Canadian provinces and territories, enhancing the country's domestic vaccine production capacity and health security. This locally produced vaccine targets the SARS-CoV-2 LP.8.1 variant and has received regulatory approvals in Canada and internationally, with preparations underway for the 2025-2026 respiratory virus season. Moderna CEO Stéphane Bancel highlighted the company's commitment not only to infectious diseases but also to future mRNA applications in cancer, rare genetic, and autoimmune diseases, reinforcing Moderna's role in advancing public health innovation. These developments demonstrate Moderna's strategic focus on scientific leadership, economic growth, and expanding access to cutting-edge mRNA medicines.